ArticleScientific reports2025
Development and evaluation of a hybrid capture-based NGS panel for comprehensive detection of respiratory pathogens.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diagnostic Insights Into Pathogen Spectrum and Mixed Microbial Detection in Critically Ill Patients With Pulmonary Infection Using Targeted Next-Generation Sequencing.Canadian respiratory journal · 2026Article
- BCS2.0: a capture sequencing platform for rapid differential diagnosis of bacterial infections and antimicrobial resistance.Frontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Infectious diseases caused by diverse pathogens-including viruses, bacteria, and fungi-pose a significant diagnostic challenge, especially when conventional assays fail to identify the causative agents. Next-generation sequencing (NGS), particularly hybrid-capture-based NGS, offers a culture-independent approach for comprehensive pathogen detection directly from clinical samples. In this study, we developed a hybrid-capture-based NGS panel targeting 85 respiratory pathogens (62 viruses, 23 bacteria/fungi) and evaluated its analytical and clinical performance. Analytical validation using 50 pathogens demonstrated high sensitivity, with 10× genome coverage ≥ 96% in 32 of 36 viral targets and ≥ 95% in all 14 bacterial/fungal targets. The panel maintained ≥ 80% genome coverage at Ct values up to 34. Clinical assessment of 561 respiratory specimens identified 25 pathogen species, achieving ≥ 90% genome coverage in 57.5% of virus-positive and 83.6% of bacteria-positive samples. Notably, additional pathogens were detected in high Ct value undetected by RT-PCR, and 35 cases of viral-viral and viral-bacterial co-infections were identified. This approach improves the detection performance for respiratory infections of unknown etiology and serves as a practical platform for the detection of emerging pathogens and public health preparedness. This technology has significant potential for applications in infectious disease surveillance and development of vaccines and therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.